Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients

Simple item page
dc.contributor.authorYılmaz, Yusuf
dc.contributor.buuauthorGül, Özen Öz
dc.contributor.buuauthorTuncel, Ercan
dc.contributor.buuauthorUlukaya, Engin
dc.contributor.buuauthorGül, Cuma Bülent
dc.contributor.buuauthorKıyıcı, Sinem Küçüksaraç
dc.contributor.buuauthorOral, Arzu Yılmaztepe
dc.contributor.buuauthorGüçlü, Metin
dc.contributor.buuauthorErsoy, Canan
dc.contributor.buuauthorİmamoğlu, Şazi
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-0463-6818tr_TR
dc.contributor.orcid0000-0003-2467-9356tr_TR
dc.contributor.researcheridA-5841-2017tr_TR
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.researcheridABI-4847-2020tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.researcheridK-5792-2018tr_TR
dc.contributor.researcheridA-7063-2018tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid7006929833tr_TR
dc.contributor.scopusid6602927353tr_TR
dc.contributor.scopusid23988796000tr_TR
dc.contributor.scopusid12753880400tr_TR
dc.contributor.scopusid23091316500tr_TR
dc.contributor.scopusid15073842600tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid6602297533tr_TR
dc.date.accessioned2022-09-07T11:41:28Z
dc.date.available2022-09-07T11:41:28Z
dc.date.issued2010-01
dc.description.abstractLow levels of soluble receptor for advanced glycation end products (sRAGE) have been associated with the occurrence of vascular complications in patients with type 2 diabetes mellitus. Preliminary evidence has suggested that thiazolidinediones have the ability to modulate circulating levels of this molecule in the hyperglycemic milieu. The aim of this pilot study was to assess the differential effect of 2 different thiazolidinediones pioglitazone and rosiglitazone on plasma levels of sRAGE in type 2 diabetes mellitus patients. Sixty type 2 diabetes mellitus subjects were randomly assigned to receive pioglitazone (30 mg/d, n = 19), rosiglitazone (4 mg/d, n = 20), or placebo (medical nutrition therapy, n = 21) for 12 weeks. Changes in plasma glucose, glycosylated hemoglobin, insulin resistance (homeostasis model assessment), total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and sRAGE were evaluated at baseline and after 12 weeks. At 12 weeks, the pioglitazone (P < .001) group had a significant increase from baseline in sRAGE values that was not seen in the medical nutrition therapy and rosiglitazone groups. We conclude that, in type 2 diabetes mellitus patients, pioglitazone but not rosiglitazone significantly raised sRAGE, which may contribute to its antiatherogenic effects.en_US
dc.identifier.citationGül, Ö. Ö. vd. (2010). "Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients". Metabolism: Clinical and Experimental, 59(1), 64-69.en_US
dc.identifier.endpage69tr_TR
dc.identifier.issn0026-0495
dc.identifier.issn1532-8600
dc.identifier.issue1tr_TR
dc.identifier.pubmed19709689tr_TR
dc.identifier.scopus2-s2.0-72049115492tr_TR
dc.identifier.startpage64tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.metabol.2009.07.006
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0026049509002790
dc.identifier.urihttp://hdl.handle.net/11452/28539
dc.identifier.volume59tr_TR
dc.identifier.wos000276761500011tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherW B Saunders Co-Elsevieren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalMetabolism: Clinical and Experimentalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSerum-levelsen_US
dc.subjectTherapeutic implicationsen_US
dc.subjectMyocardial-infarctionen_US
dc.subjectCardiovascular risken_US
dc.subjectEndproducts srageen_US
dc.subjectRageen_US
dc.subjectDiseaseen_US
dc.subjectFormen_US
dc.subjectExpressionen_US
dc.subjectHypercholesterolemiaen_US
dc.subjectEndocrinology & metabolismen_US
dc.subject.emtreeAdvanced glycation end product receptoren_US
dc.subject.emtreeGlucoseen_US
dc.subject.emtreeGlycosylated hemoglobinen_US
dc.subject.emtreeHemoglobin A1cen_US
dc.subject.emtreeHigh density lipoprotein cholesterolen_US
dc.subject.emtreeLow density lipoprotein cholesterolen_US
dc.subject.emtreePioglitazoneen_US
dc.subject.emtreeRosiglitazoneen_US
dc.subject.emtreeTriacylglycerolen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAtherogenesisen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeCholesterol blood levelen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiabetic dieten_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeGlycemic controlen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInsulin resistanceen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProtein blood levelen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeTriacylglycerol blood levelen_US
dc.subject.meshBlood glucoseen_US
dc.subject.meshBody mass indexen_US
dc.subject.meshDiabetes mellitus, type 2en_US
dc.subject.meshFemaleen_US
dc.subject.meshGlycosylation end products, advanceden_US
dc.subject.meshHemoglobin A, glycosylateden_US
dc.subject.meshHumansen_US
dc.subject.meshHypoglycemic agentsen_US
dc.subject.meshInsulin resistanceen_US
dc.subject.meshLipidsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPilot projectsen_US
dc.subject.meshPlacebosen_US
dc.subject.meshReceptors, immunologicen_US
dc.subject.meshSolubilityen_US
dc.subject.meshThiazolidinedionesen_US
dc.subject.scopusDiabetes Mellitus; 6 N Carboxymethyllysine; Glycationen_US
dc.subject.wosEndocrinology & metabolismen_US
dc.titleComparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patientsen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus